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In our previous studies, we have purified a unique, paired basic residue-specific, prohormone-converting enzyme from 
pituitary intermediate lobe secretory vesicles. This enzyme, an aspartyl protease, was shown to cleave the intermediate 
lobe prohormone, pro-opiomelanocortin (POMC), to adrenocorticotropin, Bendorphin and a 16 kDa NH,-terminal gly- 
copeptide, in vitro [(1985) J. Biol. Chem. 260, 719472051. To provide some evidence that this enzyme plays a role in 
prohormone conversion in the intact cell, the ability of pepstatin A, an aspartyl protease inhibitor, to block POMC pro- 
cessing in the mouse intermediate pituitary was investigated. By the use of a radioactive pulse-chase paradigm, PH]POMC 
processing was found to bc inhibited by 36.4% in pepstatin A-treated intermediate lobes. This result is consistent with 
the inactivation of pro-opiomelanocortin-converting enzyme by pepstatin A in the intact pituitary and further supports 
a role of this enzyme in POMC processing in vivo. 
Prohormone processing enzyme; Intermediate lobe; ACTH/endorphin prohormone; Aspartyl protease; Protease inhibitor 
1. INTRODUCTION 
The conversion of pro-opiomelanocortin 
(POMC, ACTH/endorphin prohormone) in the 
intermediate pituitary to yield biologically active 
hormones requires a sequence of enzymatic post- 
translational processing steps which occur within 
secretory vesicles [l-3]. The first cleavages take 
place at pairs of basic amino acid residues which 
flank the hormones to be cleaved. In a previous 
study, we reported the purification from bovine in- 
termediate pituitary secretory vesicles, a PCE that 
is specific for paired basic residues of POMC [4]. 
The enzyme processed POMC to yield ACTH, ,8- 
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endorphin and a 16 kDa NHz-terminal glycopep- 
tide [4]. Recently PCE was also shown to cleave 
NHz-terminal POMC l-76 at the Arg-Lys pair to 
yield products, identified by retention times on 
high-performance liquid chromatography and im- 
munoreactivity, as Lys-y3-MSH and NHz-terminal 
POMC l-49 (Estivariz, F., Birch, N.P. and Loh, 
Y.P., in preparation). PCE was characterized as a 
70 kDa glycoprotein with a pH optimum of 
4.0-5.0 [4]. It was inhibited by pepstatin A and 
diazoacetyl-norleucine methyl ester, both aspartyl 
protease inhibitors, but not by thiol or serine pro- 
tease inhibitors [4,5]. An enzyme activity with 
similar specificity and characteristics has also been 
found in rat intermediate and anterior pituitary 
secretory vesicles [6,7]. 
The involvement of PCE in POMC processing in 
vivo is supported by (i) its localization in secretory 
vesicles, the intracellular site of processing [3]; (ii) 
its specificity for paired basic residues of POMC; 
(iii) its acidic pH optimum, consistent with the 
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acidic internal environment of secretory vesicles 
[4,8] and (iv) its co-secretion with wMSH (a 
POMC-derived hormone), in a co-ordinately 
regulated manner [9]. To provide some evidence 
for a physiological role of PCE in prohormone 
conversion in the intact cell, the ability of pepstatin 
A, an inhibitor of this enzyme, to interfere with 
POMC processing in pituitary cells was examined. 
In this study we show that POMC processing was 
inhibited in pepstatin A-treated mouse pituitary in- 
termediate lobe cells. 
2. MATERIALS AND METHODS 
2.1. Animals 
White, male mice (NIH strain) weighing 25-30 g were ob- 
tained from the National Institutes of Health animals facilities 
(Bethesda, MD). 
2.2. Analysis of neurointermediate lobes treated with 
pepstatin A and pulse-chase incubated in [1’Hlarginine 
Pituitary nemointermediate lobes were dissected from mice. 
Since only the intermediate lobe synthesizes pro- 
opiomelanocortin, and the neural lobe does not, the two lobes 
were not separated for these biosynthesis studies. 
Neurointermediate lobes were pre-incubated at 37°C for 45 min 
in mammalian Ringer’s solution [3] in the presence or absence 
of pepstatin A (10m4 M). Lobes were then pulse incubated for 
10 min in Ringer’s solution containing 18 /rM [3H]arginine 
(spec. act. 18 mCi/mmol, purchased from DuPont-New 
England Nuclear Corp., Boston, MA) with or without pepstatin 
A, followed by a chase incubation for 2 h in Ringer’s solution 
containing 1 mM unlabelled arginine + pepstatin A. The lobes 
were then homogenized in 0.1 N HCI. Homogenates were either 
immunoprecipitated with antiserum specific for the mid- 
portion of ACTH (DP4), or analyzed directly on 11% 
polyacrylamide acid-urea gels [lo]. The medium from the chase 
incubation was also collected, acidified to a final concentration 
of 0.1 N HCl and analyzed by acid-urea gels. In some ex- 
periments, lobes were inhibited from secretion by dopamine (5 
x lo-’ M), included in the chase-incubation medium [II]. 
Dopamine does not affect the processing of POMC [ 111. Pulse- 
chase incubation and immunoprecipitation procedures have 
been described in detail elsewhere [3]. Since pepstatin A was 
solubilized in DMSO, the incubation medium contained a final 
concentration of 0.1% DMSO. Control experiments indicate 
that 0.1% DMSO did not affect the lobes’ ability to incorporate 
[3H]arginine, the morphology of the cells as evidenced by elec- 
tron microscopy and the ability of the cells to show regulated 
secretion. 
2.3. Preparation and characterization of subcellular fractions 
Twenty neurointermediate lobes were pooled after a 45 min 
preincubation, 10 min pulse in [3H]arginine and a 2 h chase in- 
cubation in medium containing pepstatin A, as described 
above. Dopamine (5 x 10-s M) was also included in the chase 
incubation to block secretion. The lobes were homogenized in 
0.25 M sucrose/l0 mM Tris-Cl, pH 7.4 at 0°C and the 
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Fig. 1. Acid-urea gel profiles of [‘Hlarginine-labelled proteins 
from control and pepstatin A-treated neurointermediate lobes 
and secretion medium. (A) Acid-urea gel profiles of lobes pulse 
labelled in [3H]arginine for 10 min with (O---O) and without 
pepstatin A ( -). (B) Acid-urea gel profiles of a lobe pulse 
labelled in [‘Hlarginine for 10 min and chase incubated for 2 h 
(-), chase medium (O---O) and chase medium from a lobe 
pulse labelled for 10 min and chase incubated for 2 h in the 
presence of dopamine (a). (C) Acid-urea gel profiles of a 
lobe pulse labelled in [‘Hlarginine for 10 min and chase 
incubated for 2 h in the presence of pepstatin A ( -), chase 
medium from the pepstatin A-treated lobe (O---O) and chase 
medium from a lobe pulse labelled for 10 min and chase 
incubated for 2 h in the presence of pepstatin A and dopamine 
(M). 
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homogenate was then subjected to differential centrifugation at 
4°C (described in detail elsewhere) [3]. The fractions generated 
were: P I (cell debris and nuclei), P II (mitochondria/secretory 
vesicle fraction), P III (secretory vesicle fraction), P IV 
(microsomal fraction) and the supernatant. The fractions were 
characterized by the distribution of monamine oxidase 
(mitochondria marker) and wMSH (secretory vesicle marker). 
Each fraction was suspended in 0.1 N HCl, im- 
munoprecipitated with ACTH antiserum and analyzed for 
POMC by acid-urea gel electrophoresis as described previously 
[41. 
3. RESULTS 
Neurointermediate lobes were pulse labelled for 
10 min and homogenized, or chase incubated for 
2 h. Fig.lA shows that with a pulse incubation 
alone, POMC, previously identified by its elec- 
trophoretic and immunological properties [3], was 
the major peak seen in the acid-urea gel profiles, in 
both control and pepstatin A-treated lobes. Incor- 
poration of [3H]arginine into POMC in pepstatin 
A-treated lobes was quantitatively within the same 
range as control lobes (not shown), indicating that 
pepstatin A did not affect POMC synthesis. In 
control lobes that were pulse labelled and chase in- 
cubated for 2 h (fig.lB), POMC was significantly 
processed (table 1) to various products including 
21-23 kDa ACTH intermediates, which had 
previously been identified by immunoprecipitation 
131. These products were secreted into the medium 
and the secretion was inhibited by dopamine. In 
contrast, pepstatin A-treated lobes, after a 2 h 
chase incubation, showed a major POMC peak 
and significantly less processed products (fig.lC). 
The small amount of processed products formed 
were similar to those found in control lobes (fig. 1B 
and C) and these products were secreted into the 
medium, in a dopamine inhibitable manner. 
However, most of the unprocessed POMC was not 
secreted (fig. 1C). Quantitative analysis (table 1) 
revealed a 36.4% inhibition of POMC processing 
with pepstatin A treatment, relative to control. A 
similar level of inhibition of POMC processing by 
pepstatin A was observed in lobes treated in the 
same manner, except that dopamine was added to 
inhibit secretion (not shown). 
The lack of secretion of the unprocessed POMC 
prompted the investigation into whether pepstatin 
A treatment interfered with the packaging of the 
prohormone into secretory vesicles for processing, 
which normally occurs in untreated lobes [3]. 
Pepstatin A-treated lobes that were pulse labelled 
and chase incubated in dopamine for 2 h, were 
subcellularly fractionated to determine the 
distribution of [3H]POMC within the cell. Fig.2 
shows the gel profile of 3H-labelled, anti-ACTH 
immunoprecipitated, POMC and various 
Table 1 
Analysis of inhibition of POMC processing by pepstatin A in mouse neurointermediate lobes 
Treatment % 
i 
POMC cpm 
a % POMC % inhibition 
POMC cpm + products cpm conversion 
Control lobes (10 min pulse) 71.5 + 5.6 (2) 
Control lobes + medium 
(10 min pulse-2 h chase) 15.9 * 2.0 (4) 77.8 
Pepstatin A-treated lobes 
(10 min pulse) 67.9 + 4.8 (2) 
Pepstatin A-treated lobes + 
medium (10 min pulse-2 h chase) 34.3 * 1.4 (4) 49.5 36.4 
a Values shown are the mean k SD. The number of lobes analyzed is shown in parentheses. cpm in 
POMC peak (gel slices 16-20) and product peaks (gel slices 21-50) were taken from acid-urea gel 
profiles as shown in fig.1 
% POMC conversion = 100% - I 
% (POMWPOMC + prOdUCtS)tchase = 2 h 
x loo 
% (POMWPOMC + prOdUCtS)f,h,,, = 0 h I 
% inhibition = 100% - 
% conversion in pepstatin A-treated lobes 
x 100 
% conversion in control lobes I 
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Fig.2. Acid-urea gel profile of anti-ACTH immunoprecipitated 
proteins from pepstatin A-treated nemointermediate lobes. 
Lobes were pulse labelled in [‘Hlarginine for 10 min and chase 
incubated for 2 h in the presence of dopamine and pepstatin A. 
(Inset) Subcellular distribution of anti-ACTH immuno- 
precipitated [3H]POMC and immunoreactive cr-MSH (see 
section 2). 
21-23 kDa ACTH intermediates and ACTH pro- 
ducts (13 and 4.5 kDa) from pepstatin A-treated 
lobes. Note that POMC is the predominant peak, 
indicating inhibition of processing in these lobes. 
Fig.2 (inset) shows that anti-ACTH im- 
munoprecipitated POMC was primarily present in 
fractions (P II and P III) which contain cu-MSH, 
the marker for secretory vesicles. Essentially no 
POMC was found in the microsomal fraction 
(P IV, which contains Golgi and rough en- 
doplasmic reticulum). These results suggest that 
POMC in pepstatin A-treated lobes was in- 
tracellularly transported into secretory vesicles and 
not retained in the Golgi apparatus or rough en- 
doplasmic reticulum. 
4. DISCUSSION 
Many mammalian prohormone processing en- 
zymes that cleave at paired basic residues have 
been reported [4,12-181. While evidence such as 
the specificity, localization in secretory vesicles 
and the acidic pH optimum have suggested that 
some of these enzymes may play a physiological 
role in prohormone processing, none have been 
shown directly to function in the intact cell. 
Evidence for direct participation of an enzyme in 
prohormone processing in the intact cell may be 
obtained by several ways: by showing (i) that a mu- 
tant that fails to process the prohormone lacks the 
enzyme; (ii) that an anti-sense mRNA to the en- 
zyme introduced into the cell blocks the expression 
of the enzyme and hence processing of the prohor- 
mone, or (iii) that treatment of intact cells with an 
inhibitor of the enzyme prevents prohormone pro- 
cessing. The lack of appropriate mammalian 
mutants and the experimental difficulties inherent 
in these. approaches have rendered the demonstra- 
tion of the involvement of a putative processing 
enzyme in prohormone conversion in the intact 
tissue, a formidable task. In this study, we have at- 
tempted to show that the secretory vesicle, paired 
basic residue-specific, PCE [4] participates in pro- 
hormone processing in the intact pituitary using 
the third approach. Pepstatin A is a potent in- 
hibitor of PCE [4] and it is a hydrophobic peptide 
which is capable of entering cells and accumulating 
in organelles [19]. We showed that treatment of 
mouse neurointermediate lobes with pepstatin A 
resulted in a 36.4% inhibition of POMC process- 
ing as compared to untreated lobes (fig. 1, table 1). 
Subcellular fractionation studies indicate that 
POMC was transported and packaged into 
secretory vesicles. Hence, the inhibition of POMC 
processing in pepstatin A-treated lobes was not due 
to an effect on intracellular routing of POMC into 
secretory vesicles, but rather an inhibitory effect of 
this agent on an aspartyl protease, presumably the 
PCE activity [4] in secretory vesicles. The level of 
inhibition of POMC processing by pepstatin A is 
dependent on the efficiency of entry of the in- 
hibitor into the cells and accumulation in sufficient 
concentrations in the secretory vesicles. Complete 
inhibition of POMC processing would occur only 
when there is total inactivation of all PCE 
molecules within the cells. Such conditions are 
probably not experimentally achievable, especially 
since the intact intermediate lobe has only a finite 
time of viability in vitro and therefore, the treat- 
ment time cannot be more extensive. In view of 
these experimental constraints, the incomplete in- 
hibition of POMC processing by pepstatin A 
observed in intact mouse intermediate lobes was 
perhaps not surprising. Nevertheless, the in- 
hibitory effect of pepstatin A was significant and 
highly reproducible. 
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The release studies showed that the unprocessed 
POMC in the pepstatin A-treated lobes was not 
secreted. Preliminary autoradiographic studies at 
the electron microscopic level on pepstatin A- 
treated mouse intermediate lobes that were pulsed 
in [3H]arginine for 10 min and chase incubated for 
2 h, revealed silver grains associated with secretory 
vesicles that were primarily localized in the prox- 
imity of the Golgi apparatus. In correlation with 
the subcellular fractionation data, these vesicles 
probably contain unprocessed POMC, raising the 
hypothesis that the prohormone processing event 
within the secretory vesicle may be a prerequisite 
for its mobilization towards the plasmalemma for 
secretion. 
In summary, this study has demonstrated that 
an inhibitor of PCE can block processing of 
POMC in intact intermediate pituitary cells. These 
data add to the existing evidence (described in sec- 
tion 1) in providing strong support for the par- 
ticipation of PCE in POMC processing in 
intermediate pituitary cells in vivo. 
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